Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, has announced the pricing of an underwritten offering of 37,931,035 shares of its common stock at a price of US$2.90 per share. The gross proceeds from this offering are expected to be approximately US$110 million, before deducting the underwriting discount and commissions and estimated offering expenses payable by Allogene.
Latham & Watkins LLP represented the sole book-running manager in the offering, with a capital markets team led by Orange County partner Shayne Kennedy and Bay Area partner Phillip Stoup, with associates Tess Bloom and Taimi Jacobson. Advice was also provided on IP matters by Bay Area partner Judith Hasko, with associate Patrick Chew.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
